EVRY, France, June 27, 2016 -- Global Bioenergies (Alternext Paris: ALGBE) announces having delivered isobutene produced at its industrial pilot to Clariant, a leading specialty chemical company.
Clariant is a Swiss stock-market listed company with revenues exceeding 5 billion euros in 2015, active in a variety of chemical markets such as specialty polymers.
Global Bioenergies' most advanced program consists in the production of high-purity isobutene from renewable resources. A sample of such renewable isobutene, produced at the company's industrial pilot plant, has been shipped to Clariant, where tests regarding Clariant's application of interest have been carried out successfully.
Thomas Buhl, Head of Business Development at Global Bioenergies comments: "After Cristal Union, Audi, Arkema, CFBP, Arlanxeo and L'Oréal, we are pleased to add a seventh company to our list of major industrialists interested in our technology. Clariant is known for developing innovative solutions towards a more environment-friendly chemistry, a mission shared by Global Bioenergies."
About GLOBAL BIOENERGIES
Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performances of its process, operates its industrial pilot, builds its demo plant in Germany, and prepares the first full-scale plant through a Joint-Venture with Cristal Union, named
IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 - ALGBE).
Should you like to be kept informed, subscribe to our news feed on
www.global-bioenergies.com
Follow us on Twitter: @GlobalBioenergi
Contact
GLOBAL BIOENERGIES
Thomas BUHL
Head of Business Development
Phone: +33 (0)1 64 98 20 50
Email: [email protected]
Press release http://hugin.info/166909/R/2023313/751756.pdf
HUG#2023313


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



